Entering the market is one challenge. Building sustainable growth is another. For many international healthcare manufacturers, entering Brazil represents a significant milestone. Regulatory approval is secured.A local distributor is appointed.Commercial activities begin. On paper, everything seems ready for growth. Yet many companies discover a frustrating reality: Market entry does not guarantee market expansion. In fact, some of the biggest challenges begin after launch. The Illusion of Market Entry Many organizations approach Brazil with a project mindset. The objective becomes obtaining approval, establishing representation and initiating sales. While these are important steps, they’re only the foundation. Growth requires something different. It requires a long-term market access strategy. Manufacturers that focus exclusively on launch often underestimate the complexity of building sustainable demand across a market as large and diverse as Brazil. Brazil Is Not One Market One of the most common mistakes made by foreign companies is treating Brazil as a single commercial environment. The reality is far more complex. Healthcare market variations across Brazil include: What works in São Paulo may not work in Recife, Porto Alegre or Manaus. Scaling requires regional understanding. Market entry does not guarantee market expansion. In fact, many challenges begin after launch. The Distribution Dependency Trap Many manufacturers rely heavily on a single distribution structure. Initially, this seems efficient. Over time, however, it can create significant limitations: Limited visibility into market dynamics.Restricted regional reach.Dependence on a small number of relationships.Reduced adaptability. Successful growth often depends on developing a broader ecosystem capable of generating intelligence, access and execution across multiple regions. Market Intelligence Is Often Missing Most manufacturers monitor sales. Fewer understand the factors driving those sales. Questions that are frequently difficult to answer: Without visibility, expansion becomes reactive. And reactive growth rarely scales efficiently. Sustainable Growth Requires Ecosystem Thinking The most successful organizations no longer view growth as a linear process. They understand that growth emerges from connected networks. Manufacturers need more than distributors. They need intelligence.They need visibility.They need access to market signals.They need coordinated execution. In other words, they need an ecosystem. The Next Generation of Market Access The future of healthcare expansion in Brazil will belong to companies capable of combining: Winning manufacturers will integrate: The winners will not necessarily be those with the largest portfolios. They’ll be those with the strongest ecosystem. Success in Brazil isn’t defined by how quickly you enter. It’s defined by how effectively you scale. GroPO’s Vision At GroPO, we believe sustainable growth requires more than market entry. It requires market integration. Our mission is to connect manufacturers, distributors and hospitals through intelligence, visibility and execution. We provide the ecosystem infrastructure that enables manufacturers to: Because success in Brazil is not defined by how quickly you enter the market. It is defined by how effectively you scale within it. Build Your Brazil Scaling Strategy Let’s discuss how to move from market entry to sustainable market expansion.

O futuro da saúde será definido pela capacidade de conectar inteligência, execução e colaboração A cadeia healthcare nunca teve acesso a tanta informação. Dados estão por toda parte. Hospitais geram dados.Fabricantes geram dados.Distribuidores geram dados. E, ainda assim, a sensação predominante em muitos mercados é a mesma: Falta conexão. Essa é uma das grandes contradições do setor. Temos mais informação do que nunca, mas continuamos enfrentando problemas relacionados à falta de visibilidade, previsibilidade e coordenação entre os diferentes participantes da cadeia. O modelo tradicional está chegando ao seu limite Historicamente, fabricantes, distribuidores e hospitais operaram de forma relativamente independente. Cada organização buscava otimizar seus próprios processos. Cada elo desenvolvia suas próprias ferramentas, indicadores e estratégias. Esse modelo funcionou durante muito tempo. Mas a crescente complexidade do healthcare tornou suas limitações cada vez mais evidentes. Quando as decisões são tomadas de forma isolada, surgem desafios como: O problema não está em cada organização individualmente. O problema está na falta de conexão entre elas. O futuro não pertence aos atores isolados. Pertence aos ecossistemas capazes de aprender, colaborar e evoluir juntos. O poder dos ecossistemas Os setores mais avançados da economia já entenderam que a geração de valor acontece em rede. Empresas que antes competiam apenas pela eficiência operacional passaram a competir pela qualidade de seus ecossistemas. No healthcare, esse movimento está apenas começando. Um ecossistema conectado permite que diferentes participantes compartilhem: Isso gera benefícios para todos os envolvidos: Fabricantes ampliam sua capacidade de acesso ao mercado.Distribuidores fortalecem sua relevância estratégica.Hospitais ganham eficiência e previsibilidade. Dados não são suficientes Existe uma crença comum de que a transformação digital acontece apenas através da tecnologia. Mas tecnologia sem conexão gera apenas mais informação. O verdadeiro diferencial competitivo surge quando dados se transformam em decisões e decisões se transformam em execução. É essa capacidade de transformar informação em ação coordenada que diferencia ecossistemas maturos de mercados fragmentados. O próximo ciclo do healthcare O futuro do setor não será definido apenas por novos produtos ou novas tecnologias. Será definido pela capacidade de criar ambientes mais colaborativos, inteligentes e conectados. Os líderes da próxima década serão aqueles capazes de construir pontes entre os diferentes participantes da cadeia. Porque nenhum elo, isoladamente, consegue resolver os desafios de um mercado tão complexo. Inteligência + Execução + Colaboração = O futuro do healthcare. A Visão da GroPO Na GroPO, acreditamos que a próxima evolução do healthcare passa pela construção de ecossistemas inteligentes. Nossa visão é conectar fabricantes, distribuidores e hospitais em uma estrutura capaz de gerar: Porque o futuro da saúde não pertence aos atores isolados. Pertence aos ecossistemas capazes de aprender, colaborar e evoluir juntos. Faça Parte do Ecossistema Conectado Descubra como GroPO está transformando a forma como healthcare opera. Envie um EmailWhatsAppConheça GroPO

Por que muitos dos desafios operacionais dos hospitais começam antes mesmo do atendimento ao paciente Quando falamos sobre eficiência hospitalar, normalmente pensamos em processos assistenciais, tecnologia médica ou gestão clínica. Mas existe um fator que impacta diretamente a performance das instituições de saúde e que muitas vezes recebe menos atenção do que deveria: A fragmentação da cadeia de suprimentos. Embora seja pouco visível para quem está fora da operação, seus efeitos são percebidos diariamente por gestores, equipes de compras e lideranças hospitalares. A consequência é clara: Mais esforço para gerar os mesmos resultados. Uma cadeia complexa por natureza O ambiente hospitalar depende da interação constante entre diversos atores: A cadeia de suprimentos hospitalar inclui: Quando esses participantes operam de forma desconectada, surgem dificuldades que comprometem a eficiência de toda a cadeia. Não se trata apenas de abastecimento. Trata-se de visibilidade, previsibilidade e capacidade de coordenação. O impacto da falta de integração A fragmentação costuma gerar problemas que parecem isolados, mas que na verdade possuem uma mesma origem. Entre os desafios operacionais comuns: Quando somados, esses fatores criam custos operacionais significativos. Custos que muitas vezes não aparecem diretamente nas planilhas, mas impactam produtividade, planejamento e eficiência. Mais esforço para gerar os mesmos resultados. Esse é o custo invisível da fragmentação. Previsibilidade tornou-se um ativo estratégico Durante muito tempo, o foco da gestão hospitalar esteve concentrado em controlar custos. Hoje, o desafio é mais amplo. Hospitais precisam construir previsibilidade. A capacidade de antecipar demandas, compreender movimentos do mercado e planejar compras de forma mais inteligente tornou-se uma vantagem competitiva. Quanto maior a previsibilidade, menor a exposição a riscos operacionais e rupturas. O futuro será construído por ecossistemas conectados A transformação da cadeia hospitalar não depende apenas de tecnologia. Depende de conexão. Os hospitais mais eficientes do futuro serão aqueles capazes de atuar dentro de ecossistemas mais integrados, onde fabricantes, distribuidores e instituições de saúde compartilham informações, inteligência e objetivos comuns. Ecossistemas conectados geram: Da fragmentação à inteligência Dados, isoladamente, não resolvem problemas. O verdadeiro valor surge quando informações se transformam em inteligência para tomada de decisão. A evolução do healthcare passa justamente por essa capacidade de conectar pessoas, organizações e informações em uma cadeia mais colaborativa. Dados isolados são commodidade. Inteligência conectada é o diferencial. Quem se beneficia com a integração? Cadeias de suprimentos conectadas beneficiam todos os envolvidos: Fabricantes ganham melhor visibilidade de demanda real.Distribuidores operam com maior eficiência e informações claras.Hospitais reduzem complexidade operacional e custos.E, em última análise, pacientes recebem atendimento através de sistemas mais eficientes. A Visão da GroPO Na GroPO, acreditamos que a eficiência hospitalar não começa apenas dentro dos hospitais. Ela começa na qualidade das conexões entre todos os participantes da cadeia. Nossa missão é aproximar fabricantes, distribuidores e hospitais por meio de inteligência, colaboração e execução coordenada. Porque uma cadeia mais integrada gera melhores resultados para todos — especialmente para quem está no centro dela: O paciente.

Why international manufacturers fail when they treat Brazil as a regulatory project instead of a market ecosystem. Brazil is one of the most attractive healthcare markets in the world. With a population of over 200 million people, a complex hospital network and growing demand for medical innovation, the country naturally attracts international manufacturers looking for expansion opportunities. Yet many companies underestimate one critical reality: Entering Brazil is not simply a regulatory challenge. In fact, regulation is often just the first layer of complexity. The real challenge begins after approval. Brazil is not one healthcare market Many international companies approach Brazil as if it were a centralized market. It is not. Brazil operates more like multiple regional healthcare ecosystems connected under one national structure. Different regions have: A strategy that works in São Paulo may completely fail in the North or Northeast regions. This creates one of the biggest challenges for international manufacturers: Market access at scale. Regulatory approval does not guarantee commercial access Obtaining regulatory approval from ANVISA is essential. But approval alone does not create: Hospital relationships.Distribution intelligence.Regional penetration.Operational execution.Or demand predictability. Many manufacturers invest heavily in regulatory processes only to discover later that they still lack: Strategic distribution.Local intelligence.Healthcare network access.And scalable commercial infrastructure. This is where many expansion strategies begin to lose efficiency. Entering Brazil is not simply a regulatory challenge. The real challenge begins after approval. The geography problem Brazil’s continental dimensions create a level of complexity that many foreign companies initially underestimate. Distribution is not simply about moving products. It is about: In healthcare, speed and reliability directly impact adoption. Manufacturers that depend on limited regional presence often struggle to scale consistently across the country. Healthcare in Brazil is relationship-driven Another common misconception is believing that healthcare growth is purely transactional. The Brazilian healthcare market is deeply relationship-oriented. Hospitals, distributors and healthcare stakeholders value: Long-term trust.Operational consistency.Technical support.And proximity. This means manufacturers need more than commercial representation. They need ecosystem integration. Data without execution has limited value Many organizations already have access to data. What they often lack is connected execution. The healthcare industry is still highly fragmented: Disconnected information.Isolated operations.Low visibility across the supply chain.And limited coordination between stakeholders. This fragmentation reduces efficiency for everyone: Manufacturers, distributors and hospitals alike. The future of healthcare expansion will depend on connected intelligence ecosystems capable of transforming information into coordinated action. The next phase of healthcare market expansion The companies that will successfully grow in Brazil over the next decade will not necessarily be the ones with the largest portfolios. They will be the ones capable of building: Intelligent partnerships.Integrated distribution networks.Operational visibility.And scalable ecosystem strategies. Brazil does not reward isolated operations. It rewards connected execution. GroPO’s Vision At GroPO, we believe the future of healthcare trade depends on integration. Manufacturers, distributors and hospitals should not operate as disconnected parts of the chain. They should operate as an intelligent ecosystem. Our mission is to transform healthcare trade through: Because entering Brazil is only the beginning. Scaling efficiently is the real challenge.

When manufacturers first look at Brazil, the focus is usually very clear. Get the product approved.Enter the market.Start building traction. And understandably so. Regulatory approval is the visible milestone. It’s measurable. Tangible. But after years of working with international manufacturers entering Brazil, we’ve noticed something important: The companies that grow sustainably here are rarely the ones focused only on the first registration. They’re the ones that structure the market correctly from the beginning. Growth problems usually start as structure problems What’s interesting is that most companies don’t notice this early on. At first, everything seems to work. The registration is approved.Importation begins.Commercial discussions move forward. Then the business starts growing. And that’s when the structure begins to show its strengths—or its limitations. We’ve seen situations where: Not because the product lacked demand. But because the original structure wasn’t designed for growth. Market entry and market expansion are different phases This is one of the most underestimated aspects of Brazil. The structure that allows a company to enter the market is not always the same structure that allows it to scale. Early on, speed tends to dominate decisions. Who can help us move quickly?How do we launch efficiently? But as operations mature, different questions emerge. How flexible is our structure?Can we adapt distribution?Can we expand without rebuilding the operation?Do we still control the strategic pieces of the business? That’s when companies realize that market entry decisions have long-term consequences. The structure that allows market entry is not always the same structure that allows scale. The companies that scale well usually think ahead early Manufacturers that navigate Brazil more smoothly tend to share one characteristic: They think beyond approval. They structure the operation with future growth in mind. That often means: At first, these decisions may seem excessive for an initial launch. Later, they become the reason growth happens more naturally. Structure creates momentum One of the biggest differences between fragmented and well-structured operations is momentum. In some cases, every new phase requires adjustment. New distributor? Rework the structure.New region? Revisit logistics and pricing.New product line? Rebuild operational flows. Growth becomes reactive. In stronger structures, expansion tends to happen with more continuity. Because the foundation was built to support movement—not just entry. Brazil rewards consistency Brazil is not a market where sustainable growth usually happens overnight. Relationships matter.Hospital adoption takes time.Commercial positioning evolves gradually. Manufacturers that perform well here often build momentum steadily. And consistency becomes easier when the underlying structure supports it. Not perfectly. Not without challenges. But with fewer constraints. The right structure is rarely the most visible decision Interestingly, manufacturers often spend enormous attention on products, approvals, and commercial plans—which makes sense. But some of the most important decisions are quieter ones. How the registration is held.How responsibilities are divided.How integrated the operation is.How adaptable the structure will be later. These are not always the most visible topics during market entry. Yet they often determine how efficiently the company grows afterward. Growth becomes easier when the operation was designed for it One of the clearest patterns we’ve seen over time is this: Companies that structure Brazil strategically early on spend less time correcting the operation later. They move with more flexibility.More visibility.And usually, more confidence. Not because the market becomes simpler. But because the operation was built to evolve with it. A different way to think about market entry Instead of asking: “How do we get into Brazil?” A more useful question may be: “How do we build a structure that supports growth once we’re there?” That shift changes priorities. And often, it changes outcomes too. The first registration is only the beginning Regulatory approval matters. But in many ways, it’s just the opening chapter. What defines long-term success in Brazil is what comes after: How the operation scales.How flexible the structure remains.And how well the business adapts as the market evolves. That journey starts much earlier than most companies expect. Usually with the decisions made before the first product is even approved.

For many international manufacturers, the concept of regulatory hosting in Brazil starts as a requirement. A local entity is needed.A registration must be held.Compliance has to be ensured. So the focus becomes operational: Who can take on this role?How do we get the product approved? And once that’s solved, attention shifts elsewhere. But over time, something becomes clear. Regulatory hosting is not just a requirement. It’s a strategic decision. Where the misunderstanding usually begins At first glance, regulatory hosting seems straightforward. A local partner holds the registration.The product is approved.The company can operate in the market. Simple. But what often isn’t fully considered is what comes with that role. The entity holding the registration is responsible for: In other words, the registration is not just a document. It’s a strategic asset. Control vs. convenience Many manufacturers prioritize speed and simplicity at the beginning. And that’s understandable. Brazil is a new market. There’s pressure to move forward. So decisions are made based on convenience. Who can take this role quickly?Who is already involved in the operation? In many cases, that leads to assigning the registration to a distributor or commercial partner. At first, it works. But over time, the trade-off becomes more visible. Because what was convenient at the beginning can limit flexibility later. What “done right” actually looks like When regulatory hosting is structured strategically, a few things change. The manufacturer maintains control over the registration, even without a local entity. Commercial relationships remain independent from regulatory ownership. The structure allows flexibility to evolve—whether expanding distribution, adjusting strategy, or entering new segments. And perhaps most importantly: Decisions can be made without being constrained by the initial setup. Removing complexity without losing control There’s a common misconception that control requires building a full local operation. Legal entity. Regulatory team. Infrastructure. In reality, that’s not always necessary. A well-structured regulatory hosting model allows manufacturers to: —without the need to build everything from scratch. That’s where the balance happens. Control without unnecessary complexity. The registration is not just a document. It’s a strategic asset. Governance matters more than structure alone Not all regulatory hosting models are the same. The difference often lies in governance. Clear agreements.Defined roles and responsibilities.Transparency in how decisions are made. These elements ensure that the manufacturer’s interests remain protected over time. Without them, even a well-intentioned structure can become restrictive. Flexibility becomes a long-term advantage Brazil is not a static market. Strategies evolve.Partnerships change.Opportunities expand into new regions or specialties. Manufacturers who build flexibility into their regulatory structure early on tend to navigate these changes more smoothly. They don’t need to rebuild their foundation every time the strategy evolves. They adjust—and move forward. A quieter advantage that becomes visible over time Interestingly, companies don’t always notice the value of a well-structured regulatory hosting model immediately. Everything works. The product is approved. Operations move forward. But over time, the difference becomes clear. Fewer constraints.More options.Greater control over direction. It’s not a visible advantage at first. But it becomes a decisive one later. A different way to think about regulatory hosting Instead of asking: “Who can hold our registration?” A more useful question might be: “How do we structure this so we maintain control as we grow?” That shift changes the outcome. Because in Brazil, the way the registration is structured can influence much more than compliance. It can shape the entire trajectory of the business. Worth getting right from the beginning Regulatory hosting is one of those decisions that’s easier to structure correctly at the start than to adjust later. And while it may seem like a technical detail, it often becomes one of the most strategic elements of market entry. If Brazil is part of your expansion plans, it’s worth looking at this piece not just as a requirement— but as a foundation.

At some point, most manufacturers entering Brazil realize something. The challenge isn’t just regulatory. And it’s not just commercial either. It’s how everything connects. Regulatory approval, importation, pricing, distribution, hospital access—each of these elements plays a role. But when they’re handled separately, things tend to move… unevenly. One part advances. Another slows down. And progress becomes harder to predict. The idea of integration sounds simple When companies hear “integrated model,” the initial reaction is usually positive. Fewer partners. More alignment. Better coordination. It makes sense. But what does that actually look like in practice? Because integration isn’t just about bringing services together. It’s about how decisions are made across them. It starts with visibility In a fragmented model, each partner sees only part of the operation. The regulatory team focuses on approval.The logistics partner focuses on importation.The distributor focuses on sales. Each one does their job. But no one sees the full picture. In an integrated model, that changes. Decisions are made with visibility across: And that visibility avoids a common problem: Decisions that make sense locally—but create friction globally. Timing becomes more predictable One of the biggest challenges in Brazil isn’t necessarily delays. It’s unpredictability. A regulatory step takes longer than expected.Importation isn’t aligned with approval timelines.Distribution starts before pricing is fully structured. Each delay on its own may seem small. But together, they disrupt momentum. When the model is integrated, timelines tend to align more naturally. Not perfectly—but more consistently. Because dependencies are understood upfront. Fewer handoffs, fewer gaps In a fragmented structure, every transition between partners is a potential risk point. Information needs to move from one party to another.Context can get lost.Interpretations may differ. And small misalignments start to appear. With fewer handoffs, that dynamic changes. Information flows more directly.Decisions don’t need to be constantly reinterpreted.And execution becomes more continuous. Strategy and execution start to align One of the most interesting effects of integration is how it connects strategy with execution. In many cases, companies define a strong strategy—but struggle in execution because the structure doesn’t fully support it. In an integrated model, those two layers are closer. Strategic decisions are made with operational realities in mind. And execution reflects the strategy more consistently. Integration is not about simplicity. It’s about alignment. It doesn’t remove complexity Brazil doesn’t become simple because the model is integrated. Regulation is still detailed.Taxation still requires attention.Hospitals still have their own processes. But complexity becomes more manageable. Because it’s being handled in a coordinated way—not in parallel silos. What it looks like from the outside For manufacturers, the difference is often felt in subtle ways. Fewer unexpected issues.Clearer timelines.More consistent communication.Better visibility into what’s happening across the operation. Not necessarily faster at every step. But smoother overall. And in a market like Brazil, that consistency makes a real difference. Aligning regulatory with commercial strategy At first glance, an integrated model may seem like a way to simplify operations. In reality, it’s more about alignment than simplification. Aligning regulatory with commercial strategy.Aligning pricing with tax structure.Aligning distribution with hospital access. When those elements move together, the operation gains stability. A more connected way to enter Brazil Manufacturers entering Brazil today have more options than before. They can build a fragmented structure and manage the connections themselves. Or they can work within a model where those connections are already built. There’s no single correct approach. But the difference between them becomes more visible over time. Especially as the business starts to scale. It’s something worth understanding early Integration tends to matter more after the operation begins. But the decision to adopt it happens before. That’s why it’s worth understanding early—before structures are defined and partners are selected. Because in Brazil, how things connect often matters just as much as the individual pieces themselves. Find out more about BPO in RA!   *Budget for registration ownership transfer, Market Access Strategy, and BPO in RA services for your company: www.brisa.com.br  

At some point, the question comes up.  Usually in a strategy meeting. Sometimes in a regional expansion discussion.  “Should we enter Brazil?”  It’s a fair question.  Brazil is the largest healthcare market in Latin America. The demand is real. The opportunity is clear.  But shortly after that first question, others start to follow.  How complex is the regulatory process? How long will it take? Who should we work with locally? What kind of structure do we need?  And this is where things become less straightforward.  Most companies don’t struggle with the decision to enter  In our experience, the decision to explore Brazil is rarely the difficult part.  The real challenge is how that decision is executed.  Because entering Brazil isn’t a single step.  It’s a sequence of interconnected choices:  Key decisions that define your Brazil operation:  Who will hold your registration  How your regulatory strategy is structured  How importation and taxation will impact your pricing  Which partners will represent your product in the market  How hospitals will actually adopt your technology  Individually, these decisions seem manageable.  But together, they define how your business will operate in Brazil for years.  Early decisions tend to stay with you  One of the characteristics of the Brazilian market is that initial structures aren’t always easy to change later.  We’ve seen companies:  • needing to restructure their distribution—but unable to do so without regulatory implications • adjusting pricing strategies due to tax structures defined early on • revisiting their market approach after realizing adoption was slower than expected  None of these situations come from poor decisions.  They come from decisions made without full visibility.  And that’s understandable—especially when entering a new market.  In Brazil, the way you enter often defines how you grow.  What usually makes the difference  When market entry works well, there’s usually a common pattern.  Companies take a step back before moving forward.  They don’t rush to appoint partners or define structures.  Instead, they spend time understanding how the pieces connect.  Regulation with commercial strategy. Distribution with hospital access. Tax structure with pricing and competitiveness.  That alignment early on tends to prevent a lot of adjustments later.  A conversation that changes perspective  Sometimes, what companies need at this stage isn’t a full plan.  It’s a clearer view of the landscape.  What are the possible models? What are the trade-offs? What tends to work—and what tends to create limitations later?  These aren’t always obvious from the outside.  And they don’t always show up in standard market entry checklists.  But they make a difference.  Brazil is complex—but not inaccessible  There’s a tendency to position Brazil as a difficult market.  And while it does require attention, most challenges become manageable with the right structure.  The companies that succeed here aren’t necessarily the ones that move the fastest.  They’re the ones that take the time to structure their entry properly.  Once that foundation is in place, things tend to move with more clarity—and more confidence.  Before moving forward, it’s worth pausing  If Brazil is on your roadmap, there’s value in pausing before making key decisions.  Not to slow things down.  But to ensure that the structure you build now will support where you want to go later.  Because in this market, the way you enter often defines how you grow.  Let’s have the right conversation early  Every manufacturer’s situation is different.  Different products. Different timelines. Different strategic priorities.  Which means there is no single “correct” model.  But there are better-informed decisions.  And those usually start with the right conversation.  If you’re evaluating Brazil, we’re always available to exchange perspectives.  No pressure. No predefined path.  Just a discussion to help you move forward with more clarity.  Find out more about BPO in RA!   *Budget for registration ownership transfer, Market Access Strategy, and BPO in RA services for your company: www.brisa.com.br  

When international manufacturers enter Brazil, the structure usually follows a familiar pattern.  One partner for regulatory. Another for legal representation. A third for importation and logistics. And one (or more) for distribution.  Four different partners. Sometimes more.  On paper, it makes sense.  Each one handles a specific part of the process. Each brings specialized expertise.  It feels structured.  But in practice, something else starts to happen.  The Hidden Cost of Fragmentation  At the beginning, the model works.  Regulatory moves forward. Importation’s arranged. Distribution’s set up.  But as operations start to scale, small misalignments begin to appear.  Communication gaps. Different timelines. Conflicting priorities.  Nothing dramatic at first.  Just friction.  But over time, that friction adds up.  We’ve seen situations where:  A regulatory update didn’t reach the logistics team in time. Importation was delayed due to missing documentation alignment. Pricing structures were affected by tax decisions made in isolation. Distribution moved ahead without full visibility of regulatory constraints.  Not because partners weren’t capable. But because they were operating independently.  More Partners Doesn’t Always Mean More Control  There’s a common assumption behind the fragmented model:  More partners = more specialization = better results.  In theory, that’s true.  In reality, it often creates something different.  More interfaces. More coordination. More room for misalignment.  And in a market like Brazil—where regulation, taxation, and operations are deeply interconnected—that misalignment can slow things down quickly.  Control doesn’t come from having more players.  It comes from having alignment between them.  The Complexity’s Not in the Parts. It’s in How They Connect.  Each component of the Brazilian market entry process’s manageable on its own.  Regulation can be navigated. Importation can be structured. Distribution can be built.  The challenge’s how these elements interact.  A regulatory decision can impact tax exposure.  A tax structure can influence pricing.  Pricing affects hospital adoption.  Distribution depends on all of the above.  When these pieces are handled separately, the connections between them often get overlooked.  And that’s where inefficiencies appear.  What Changes When the Model’s Integrated  Some manufacturers take a different approach.  Instead of coordinating multiple independent partners, they work with a structure where these elements are already connected.  Regulatory, legal representation, importation, and distribution operate within the same ecosystem.  What changes isn’t just simplicity.  It’s visibility.  With an integrated model:  Decisions are made with a full view of their impact across the operation. Timelines align more naturally. Information flows without needing to be constantly translated between different parties. And most importantly, the structure becomes easier to adapt.  Fewer Handoffs. More Continuity.  One of the biggest differences we see in integrated models’s continuity.  In a fragmented structure, every transition between partners’s a potential point of friction.  Information needs to be passed on. Context needs to be rebuilt.  Sometimes things get lost along the way.  With fewer handoffs, that process becomes smoother.  Not perfect—but more predictable.  And in a market where timing and compliance matter, predictability has real value.  It’s Not About Reducing Partners. It’s About Reducing Friction.  This isn’t about saying that multiple partners don’t work.  They can—and often do.  But they require a high level of coordination to function effectively.  And that coordination usually falls on the manufacturer.  For companies entering Brazil for the first time, that can be more demanding than expected.  An integrated approach shifts that dynamic.  Instead of managing the connections, the manufacturer works with a structure where those connections are already built.  A Different Way to Think About Control  At first glance, having multiple partners can feel like having more control.  But in practice, control often comes from clarity.  Control comes from:  Knowing how decisions in one area affect another  Understanding timelines across the entire operation  Having visibility into the full process—not just individual parts  That’s what allows companies to move with confidence.  Brazil Doesn’t Simplify Itself. But Your Structure Can.  Brazil will always have a certain level of complexity.  That’s part of the market.  But the way that complexity’s managed makes a significant difference.  Some companies experience it as friction.  Others experience it as a structured, manageable system.  The difference’s rarely the market itself.  It’s how the operation’s designed from the beginning.  One Partner Doesn’t Mean Less Capability  It often means the opposite.  When the right structure’s in place, integration brings:  Alignment — All elements working toward the same goals  Speed — Fewer delays from handoffs and miscommunication  Visibility — Full view of how decisions impact the operation  Flexibility — Easier to adapt as the market evolves  And those are the elements that tend to define successful market entry over time.  A Question Worth Asking Early  Before building a structure with multiple independent partners, it’s worth asking:  How will all of this connect once we start operating?  Because in Brazil, success isn’t just about having the right pieces.  It’s about how well they work together.  Thinking About Your Brazil Structure?  Let’s discuss whether a fragmented or integrated model makes more sense for your entry strategy.  Find out more about BPO in RA!   *Budget for registration ownership transfer, Market Access Strategy, and BPO in RA services for your company: www.brisa.com.br  

When international manufacturers start evaluating Brazil, the conversation tends to go in a very predictable direction. “Who’s the right distributor?” It’s usually one of the first questions. And it makes sense. Brazil’s a large country. Complex geography. Diverse healthcare system. So naturally, the instinct’s to solve for distribution early. Find a strong partner. Ensure national coverage. Move forward. But after working with companies entering Brazil for years, we’ve seen something that challenges that assumption. In most cases, distribution isn’t the real problem.Market access is. The Logic That Feels Right But Isn’t Enough The typical approach looks something like this: Get regulatory approval → appoint a distributor → start selling. On paper, it works. In practice, something often doesn’t click. Products are available. Stock’s in place. The distributor’s active. And yet, adoption’s slower than expected. Hospitals take time to incorporate the product. Demand builds gradually or sometimes not at all. At that point, the question shifts. “Is the distributor underperforming?” Sometimes that’s true. But often, the issue sits somewhere else. Distribution Delivers Products. Market Access Creates Demand. There’s an important distinction here. Distribution’s about logistics and reach. Getting the product into the country. Moving it across regions. Making it available. Market access is about something different. It’s about: How hospitals evaluate new technologies. How procurement decisions are made. How physicians influence adoption. How products are positioned clinically and economically. Distribution answers:Can the product get there? Market access answers:Will anyone actually use it? Why This Gap Matters in Brazil Brazil’s healthcare system’s not centralized. Hospitals operate with a high degree of autonomy. Procurement processes vary. Clinical decision making often involves multiple stakeholders. Which means that simply having a product available doesn’t guarantee adoption. We’ve seen situations where: Products were widely distributed but rarely used.Distributors had strong coverage but limited clinical engagement.Inventory was available but demand never really took off. Not because the product lacked value.But because the market hadn’t been activated. The Role Distributors Can and Can’t Play This is where expectations sometimes get misaligned. Distributors are essential. They play a critical role in navigating the market. But they’re not always structured to handle every aspect of market access. Some are excellent at logistics. Others have strong hospital relationships. A few combine both with clinical engagement. But expecting a single partner to fully bridge regulatory, commercial, and clinical dynamics—without a defined strategy can lead to gaps. And those gaps show up in adoption. What Successful Companies Tend to Do Differently Manufacturers who gain traction in Brazil usually approach the market in a more layered way. They don’t rely on distribution alone to drive growth. They think about: How the product will be positioned clinically. Which hospitals are priorities. How physicians will be engaged. What evidence’s needed for adoption. How procurement conversations will unfold. Distribution becomes one part of a broader strategy. Not the strategy itself. Market Access Starts Earlier Than Most Think One of the most important shifts we see in successful market entries’s timing. Companies that wait until after regulatory approval to think about market access often lose momentum. Those who start earlier sometimes well before approval tend to move faster once the product’s cleared. Because the groundwork’s already in place. Relationships are established. Conversations have started. The market’s more prepared. By the time the product’s available, adoption doesn’t need to start from zero. A Different Way to Approach Brazil Instead of asking: “Who should distribute our product?” A more effective question might be: “How will our product be adopted inside hospitals and what needs to happen to get there?” That shift changes everything. It expands the conversation beyond logistics. And brings focus to the elements that actually drive growth. Brazil Rewards Those Who Connect the Dots Brazil’s not an easy market. But it’s also not an unpredictable one. When regulatory strategy, distribution, and market access are aligned, things tend to move. Adoption becomes more consistent. Growth becomes more sustainable. When they’re not, companies often find themselves trying to fix the structure after the fact. And that’s where time—and opportunity—is lost. It’s Not About Distribution Alone Distribution matters. A lot. But on its own, it rarely solves the full challenge. Because in Brazil, success isn’t just about getting products into the country. It’s about getting them into the hands of physicians and into the routine of hospitals. And that requires more than reach.It requires access. Find out more about BPO in RA!   *Budget for registration ownership transfer, Market Access Strategy, and BPO in RA services for your company: www.brisa.com.br